info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Q Fever Market Share

ID: MRFR//4044-CR | 123 Pages | Author: Rahul Gotadki| April 2019

Several effective market share positioning strategies are used by Q Fever Market so that it is considered by healthcare professionals and institutions to be their best choice. One of these is the continuous innovation in diagnostic technologies. Keeping way ahead of time through introduction of cutting-edge diagnostic tools which provide accuracy and efficiency, requires Q Fever Market to invest heavily in R&D. Through bringing new and improved products consistently onto the market, the company not only acquires new customers but also keeps the existing ones thus creating a sense of trust and reliability.

Additionally, Q Fever Market mainly focuses on establishing strategic partnerships within the healthcare industry. These collaborations with hospitals, clinics, and research institutions enable connectivity as well as boosting its market presence. In health ecosystem, where major players are considered strategic partners, Q Fever Market earns more customers from its enlarged customer base and becomes more adaptable to changing dynamics in markets. Furthermore this collaborative approach has a positive effect on the firm’s market share but also enables it to benefit from fresh ideas sourced from various quarters.

Also for purposes of enhancing its market share positioning strategies; Q Fever Market adopts a customer-centric strategy. The organization pays close attention into understanding what unique needs should be addressed for healthcare professionals and related organizations. With the involvement of clients’ perspective in developing feedback mechanisms for them; Q Fever Market ensures that all its products are tailored appropriately depending on who is expected to use them among other factors. Basically this move does not only enhance satisfaction levels of such customers but also redresses issues that pain health personnel making it competitive.

Furthermore, besides being customer centricity oriented; Q Fever engages proactive marketing campaigns for its product lines. Such tactics entail marketing communications that highlight exceptional aspects or value-additions brought about by their diagnosis solutions. To ensure that HCPs consider offerings from Q fever when deciding upon tests top-of-mind recall techniques based on communication or branding strategies have been developed by this company. From awareness creation efforts to developing positive opinions towards Q Fever’s products, marketing operations of the business support its stronger market positions.

In order to influence market share, Q Fever Market knows the importance of pricing. The company has a balanced approach as far as this is concerned since its prices are competitive yet it offers quality products. By making sure that these diagnostic solutions are placed well in the markets, Q Fever Market ensures that they can be bought by numerous healthcare institutions from big hospitals to small clinics. Consequently, this pricing strategy allows individuals who consider costs when buying their items but still want to get value for money.

Lastly, an organized and efficient distribution network is a priority for Q Fever Market. Partnerships between these guys and distributors and suppliers make it possible for their products to be available across various regions. It promotes geographical expansion through an organized distribution network which allows access even to remote areas and diverse markets by Q Fever Marke thus increasing its overall market share. As such actions increase the availability of Q Fever’s products they also take part in determining her dominance in the entire market system.”

Covered Aspects:

Report Attribute/Metric Details
Base Year For Estimation   2021
Forecast Period   2022-2030
Growth Rate   4.60% (2022-2030)

Global Q Fever Market Overview


Q Fever Market Size was valued at USD 0.52 Billion in 2023. The Global Q Fever industry is projected to grow from USD 0.76 Billion in 2024 to USD 4.73 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.03% during the forecast period (2024 - 2032).


Some of the protuberant drivers supporting the growth of the Q fever market are identified as growth in the prevalence of chronic diseases and the increasing number of patients suffering from various bacterial infections.


The rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in the risk factors of Q fever, and globally growing geriatric population are expected to drive the Q fever market in coming years.


Q Fever Market Trends


Q fever is a bacterial infection caused by the bacteria Coxiella (C.) burnetii. C. burnetii has a reservoir in birds and mammals, especially cattle, sheep, and goats, and is most often an occupational disease affecting farmers, veterinarians, and slaughterhouse workers. The Q fever infection, mostly chronic Q fever is severe with complications including endocarditis, encephalitis, pneumonia, hepatitis, and splenomegaly requiring hospitalization. As per the data provided by the Centers for Disease Control and Prevention (CDC), between 2002 and 2014, the Q fever hospitalization rates were increased from 25.0% to 68.0%. In the US, the prevalence of Q fever was high in four states, namely, California, Texas, Colorado, and Illinois. Additionally, in 2014, the highest incidence rate of Q fever which was at least 1.0 case per million persons was found in Arizona, Arkansas, Colorado, Idaho, Montana, Nebraska, North Dakota, Oregon, South Dakota, Utah, and West Virginia. Moreover, according to the European Centre for Disease Prevention and Control (ECDC), in 2016, 1,102 cases of Q fever were reported in the European Union (EU)/European Economic Area (EEA), out of which 1,058 (96%) were confirmed.


Q Fever Market Segment Insights


Q Fever Type Insights


Global Q fever, by type, segmented into acute and chronic. Chronic is the leading segment, which is growing at the highest CAGR to reach USD 706.20 thousand during the forecast period. Chronic Q fever is a life threating problem and causes damage to the heart, lungs, liver, brain, and could cause diabetes as well. The major share of the chronic segment is attributed to its high prevalence.


Q Fever Diagnosis Insights


Based on diagnosis, Q fever market is segmented into serology tests and others. The serology tests account for major share with 8.32% CAGR during the forecast period. Under the serology test, Q fever is diagnosed through antibody blood tests, polymerase chain reaction (PCR) tests, immunoperoxidase staining, complement fixation, enzyme-linked immunosorbent assay (ELISA) tests, and other molecular tests.


Q Fever Treatment Insights


The Q fever market, by treatment, is segmented into antibiotic and surgery. The antibiotics segment accounts for the second largest share in the market with 7.32% CAGR during the forecast period. Surgery is an important component of treatment if patients have extensive valvular damage or indications of heart failure.


Q Fever End User Insights


On the basis of end user, the market is segmented into patients, hospitals and clinics, and others. The patient segment accounted for a considerable market share of 72.1%.


Q Fever Regional Insights


The Asia-Pacific accounted for the largest market share of 44.5% and is projected to grow at the highest CAGR of 8.57% during the forecast period. The increasing prevalence of chronic diseases such as diabetes, cancer, and bacterial infection in developing countries is the major driver for market growth. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively.  


The Asia-Pacific is followed by Europe, which accounted for a major market share. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with growing pet adoption.


The Americas accounted for a significant share in the Q fever market. It is attributed to the increasing adoption of pets, increasing preventive treatments, and care facilities for companion animals, rising technically advanced devices, and growing awareness regarding animal-transmitted diseases.


Q Fever Market Top Key Players


The prominent players in the Q fever market are 



  • Merck KGaA (Germany)

  • Teva Pharmaceutical (Israel)

  • Pfizer Inc. (US)

  • Basilea Pharmaceutica Ltd (Switzerland)

  • Sanofi S.A. (France)

  • Melinta Therapeutics, Inc. (US)

  • Bayer AG (Germany)

  • Johnson & Johnson Services, Inc. (US)

  • Yashica Pharmaceuticals (India)

  • AtoxBio (US)

  • Others


Some of the key strategies followed by the players operating in the Q fever market were innovation, product development, acquisition, and expansion.



  • In September 2017, Basilea Pharmaceutica Ltd entered into a development, manufacturing, and commercialization agreement with Gosun Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Basilea's antibiotic ceftobiprole in China, Hong Kong, and Macao.

  • In June 2017, Sanofi signed a strategic partnership with Eurapharma in Morocco. With this, Sanofi aims to strengthen its pharmaceutical business in Morocco and another African market.

  • In June 2017, Melinta Therapeutics, Inc. got FDA approval for its antibiotic drug Baxdela (delafloxacin) for clinical indications such as infections.


Q Fever Market Segmentation


Q fever Type Outlook



  • Acute

  • Chronic


Q fever Diagnosis Outlook



  • Serology Tests

  • Others


Q fever Treatment Outlook



  • Antibiotics

  • Surgery


Q fever End User Outlook



  • Patients

  • Hospitals

  • Others


Q fever Regional Outlook



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • Russia

    • France

    • Italy

    • UK

    • Rest of Europe



  • Asia Pacific

    • China

    • India

    • Japan

    • Rest of Asia Pacific



  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Rest of Latin America



  • Middle East & Africa


Available Additional Customizations



  • Company Profiles of Other Key Players

  • Cipla Inc. (India)

  • CSL Limited (Australia)


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.